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Abstract: The ligands L
1
 and L
2
 both form separable dinuclear 
double stranded helicate and mesocate complexes with Ru(II). In 
contrast to clinically approved platinates the helicate isomer of 
[Ru2(L
1
)2]
4+ 
was preferentially cytotoxic to isogenic cells (HCT116 
p53
-/-
) which lack the critical tumour suppressor gene. The mesocate 
isomer shows the reverse selectivity with the achiral isomer being 
preferentially cytotoxic towards HCT116 p53
+/+
. Other structurally 
similar Ru(II)-containing dinuclear complexes showed very little 
cytotoxic activity. This study demonstrates that alterations in ligand 
or isomer can have profound effects on cytotoxicity towards cancer 
cells of different p53 status and suggests that selectivity can be 
‘tuned’ to either genotype. In the search for compounds that can 
target difficult to treat tumours that lack the p53 tumour suppressor 
gene, [Ru2(L
1
)2]
4+ 
is a promising compound for further development.   
The transition metal helicate is one of the simplest 
architectures found in supramolecular chemistry.1 This species 
is formed by the use of a ligand which can partition into two 
separate binding sites, each of which coordinates a different 
metal ion. The cation’s coordination sphere is completed by 
another ligand which wraps around both metal ions giving (in the 
simplest form) a dinuclear double helicate [M2L2]
n+. The varieties 
of linear transition metal helicates can be diverse with examples 
containing 2, 3 and 4 ligands and between 2 – 5 metal ions 
reported.2-7 To produce a “true” helicate assembly the ligand 
must adopt an S-type arrangement where each of the metal 
binding domains coordinates a different metal ion but the ligand 
twists in the centre generating the homochiral (ΔΔ or ΛΛ) 
helicate. If the ligand coordinates two different metal ions but the 
ligand strand doesn’t twist (referred to as a C-type arrangement) 
then this “side-by-side” complex is referred to as the achiral (ΔΛ 
or ΛΔ) meso-helicate (or mesocate).8-14 
Previously, it has been demonstrated that the formation of 
mesocate and helicates can be controlled by the steric 
interactions between ligand strands. For example, the ligand L1, 
(Fig. 1) forms dinuclear self-assembled complexes with divalent 
transition metal ions e.g. [M2(L
1)2]
4+. In these species there is a 
substantial twist about the ligand strand and it adopts an S-type 
arrangement, resulting in the formation of a dinuclear double 
helicate. Reaction of divalent metal ions with L3, which contains 
a methoxy substituent on the central phenyl unit, again produces 
a dinuclear species e.g. [M2(L
3)2]
4+ but in these self-assembled 
architectures there is no twist around the ligand chain and it 
adopts a C-type arrangement giving a dinuclear double 
mesocate. The difference in structures is attributed to intra-
ligand steric interactions which governs the formation of either 
helicate or mesocate.15 
 
 
 
 
 
 
Figure 1. Ligands L
1
 R = R’ = H. L
2
 R = Me, R’ = H. L
3
 R= OMe, R’ = Me (top) 
and L
4
 (bottom). 
Whilst initially the transition metal helicate was purely of 
academic curiosity the similarity of the shape of the helicate to 
an α-helix (which is a common motif in the secondary structure 
of proteins) has fuelled interest in the potential biological 
applications resulting in the discovery of some interesting 
properties.16 For example, Hannon and co-workers have shown 
that an Fe(II)-containing dinuclear triple helicate (e.g. [Fe2L3]
4+) 
interacts strongly with duplex DNA, binding in the major 
groove,17 and displays both anti-cancer18 and anti-bacterial 
properties.19 Other Fe(II)-containing examples include Scott and 
co-workers “head-to-head-to-tail” helicates which show in vitro 
cytotoxic activity against a range of cancer cell lines with IC50 
values lower than cis-platin against HCT116 p53+/+ cancer 
cells.20  
Work has also focused upon the synthesis of Ru(II)-
containing helicates and the study of their cytotoxic activity.21 
However, whilst the formation of helicates using labile first-row 
transition metal ions is well established the formation of the 
corresponding Ru(II)-containing species is more challenging. 
This is a consequence of the reversibility of the bonding 
between labile metal ions and the ligand strands, which allows a 
number of molecular permutations to be accessed until the 
thermodynamic product is achieved. However, products arising 
from reaction with inert metal ions and ligand strands tend to 
produce kinetic products requiring the desired complexes to be 
separated, often from polymeric materials.22 
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However, despite the synthetic challenge, Ru(II) compounds 
are attractive as they have been shown to possess interesting 
photophysical, redox and cytotoxic properties.23 For example, 
Hannon and co-workers show a dinuclear triple helicate formed 
from a bis-pyridylimine and Ru(II) binds and distorts the 
structure of DNA resulting in cytotoxicity against breast cancer 
cell lines.22 A similar bis-bidentate ligand containing two 
azopyridine donor units forms an unsaturated dinuclear double 
helicate with Ru(II) (e.g. [(RuCl2)2L2]) of which both the cis/trans 
and the trans/trans show activity against HBL100 breast-cancer 
cell lines but the latter isomer exhibits 30 fold more potent 
cytotoxicity.24 To date the majority of this work has been limited 
to dinuclear triple helicates and saturated dinuclear double 
helicates have remained largely unexamined. Furthermore, 
biological activity of the helicate’s achiral twin, the mesocate, 
has not been previously reported. Herein this paper discusses 
the formation of Ru(II)-containing double helicates and gives the 
first reported examples of ruthenium mesocates. The paper also 
reports the first example of the selectivity of these compounds 
towards a cancer genotype, namely p53.  
Reaction of L1 with Ru(dmso)4Cl2 in ethylene glycol at 200°C 
produces a dark red solution after 24 hrs. Column 
chromatography produced a orange crystalline material which 
gave an ion in the ESI MS at m/z 2048 corresponding to a 
dinuclear species containing two metal ions and two ligand 
strands i.e. {[Ru2(L
1)2](PF6)3]}
+. However, examination of the 1H 
NMR showed more than one species is present and further 
chromatography showed this initial fraction could be isolated as 
two species, both of which had almost identical ions in the ESI-
MS but different signals were observed in the 1H NMR (see ESI). 
Analysis by X-ray crystallography showed that both fractions are 
dinuclear species containing two Ru(II) ions with the ligand 
partitioned into two tridentate thiazole-bipyridine domains 
separated by a triphenylene spacer unit. Each domain 
coordinates a different metal ion with the other ligand completing 
the Ru(II) coordination sphere. However, in one of the dinuclear 
complexes there is a substantial twist around the ligand axis 
giving a dinuclear double helicate 1a (Fig 2 a and b). In the other 
fraction the ligands do not twist and a “side-by-side” complex is 
produced and the resulting species is a dinuclear double 
mesocate 1b (Fig 2 c and d).  
Figure 2. The dinuclear complexes of Ru(II) with L
1
. a) and b) two views of the 
helicate 1a (Ru2(L
1
)2]
4+
) and c) and d) Two views of the dinuclear double 
mesocate 1b [Ru2(L
1
)2]
4+
. Thermal ellipsoids shown at 50% probability level. 
Hydrogen atoms and counter ions omitted for clarity. 
Ligand L2 is similar to L1 but contains a methyl substituent 
on the central phenyl ring. In an analogous fashion to L1, L2 
reacts with Ru(dmso)4Cl2 and after initial purification an orange 
crystalline material was produced which gave ions in the ESI-MS 
at m/z 2075 corresponding to {[Ru2(L
2)2](PF6)3]}
+ and 965 
corresponding to {[Ru2(L
2)2](PF6)2]}
2+ (see ESI). After further 
chromatography, these could be separated into two species and 
analysis by X-ray crystallography confirmed that these two 
species are both dinuclear assemblies i.e. [Ru2(L
2)2]
4+ but one is 
the helicate 2a (Fig 3 a and b) and other the mesocate 2b (Fig 3 
c and d). We have previously shown that in these types of ligand 
systems the helicate assembly is favoured due to inter- and 
intra-ligand π-stacking interactions within the dinuclear assembly. 
However, in the Ru(II) system the helicate and mesocate are 
formed in similar amounts, although this can slightly vary from 
reaction to reaction. Molecular modelling shows that in both 
cases the mesocate is the more stable species; for [Ru2(L
1)2]
4+ 
the mesocate 1b is more stable by 11.21 kJmol-1 whereas this is 
more pronounced for the methyl derivative ([Ru2(L
2)2]
4+) with the 
mesocate 2b 13.71 kJmol-1 more stable than the helicate isomer 
2a as would be expected due to the steric bulk of the –CH3 unit 
on the central spacer. However, due to the kinetic inert nature of 
Ru(II) both the helicates 1/2a and mesocates 1/2b can be 
isolated as the Ru(II) ion allows access to both the kinetic and 
thermodynamic products.  
Figure 3. The dinuclear complex form from reaction of Ru(II) with L
2
. a) and b) 
two views of the helicate 2a (Ru2(L
2
)2]
4+
) and c) and d) Two views of the 
dinuclear double mesocate 2b [Ru2(L
2
)2]
4+
. Thermal ellipsoids shown at 50% 
probability level. Hydrogen atoms and counter ions omitted for clarity. 
Reaction of L4 with Ru(dmso)4Cl2 in an analogous fashion 
gives after purification the dinuclear species [Ru2(L
4)2]
4+ (Fig 4). 
However, only the helicate isomer is obtained and no mesocate 
is observed. This can be attributed to the reduced flexibility of 
the diphenylene spacer and imparts a natural twist on the ligand 
strand preventing the formation of the mesocate. 
 
Figure 4. The dinuclear complex [Ru2(L
4
)2]
4+
 formed from reaction of Ru(II) 
with L
2
. Thermal ellipsoids shown at 50% probability level. Hydrogen atoms 
and counter ions omitted for clarity. 
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a 
d 
a b 
c d 
COMMUNICATION          
 
 
 
 
To investigate whether these new ruthenium helicates and 
mesocates have any cytotoxic activity against cancer cells in 
vitro, chemosensitivity studies were performed. One major 
limitation of many chemotherapeutic agents in clinical use is 
their reduced cytotoxicity towards cancer cells that lack the 
tumour suppressor p53.25-29 To investigate the impact of p53 on 
any cytotoxic activity of these novel compounds, p53 wild-type 
and p53-null isogenic cancer cell clones of the human colorectal 
cancer cell line HCT116 were utilised.30 These have been 
extensively used as in vitro cancer cell models to investigate and 
elicit p53-dependent effects.31-35 Chemosensitivity assays 
revealed that neither the methyl substituted helicate 2a or the 
diphenyl-containing helicate ([Ru2(L
4)2]
4+) were active against 
either the p53+/+ or p53-/- HCT116 cancer cells (IC50 >50µM) 
whereas the mesocate isomer (2b) showed some, albeit modest, 
activity towards the p53 wild-type cancer cells that was 
comparable to the cytotoxicity of platinate carboplatin (Fig 5a). 
The mononuclear derivative [Ru(L1)2]
2+ (see ESI), where two 
ligands are coordinated to one metal ion, showed a degree of 
potency that was comparable to cisplatin and oxaliplatin but 
lacked selectivity towards the p53+/+ or p53-/- cancer cells (Fig 
5b). The achiral mesocate 1b was also active against both cell 
lines but it was ~2-fold more active against the p53+/+ cells (Fig 
5b). In terms of selectivity, this was similar to cisplatin and 
oxaliplatin which also showed selectivity towards the HCT116 
p53+/+ cancer cells. However, the unsubstituted helicate 1a was 
substantively more cytotoxic towards the p53-/- cells (Fig 4a/b). 
This preferential cytotoxicity of the 1a helicate towards the p53-/- 
cancer cells was independently confirmed by two different 
experimental approaches. First, the transient transfection of 
wild-type p53 into these p53-/- cancer cells and resulting 
expression of p53 reduced the activity of the 1a helicate against 
the p53-/- cells such that the effects of 48h exposure to the 1a 
helicate appeared similar to that of the vehicle control (Fig 6a). 
In the converse experiment, partial knockdown of p53 (~50% 
reduction in protein expression) in the HCT116 p53+/+ cells using 
a previously validated siRNA against p5336 led to a small but 
statistically significant increase in the potency of 1a (Fig 6b). 
These results were reproduced in RKO and LoVo colorectal 
carcinoma cell lines (see ESI). Furthermore, initial studies 
demonstrate that knockdown of p53 in RKO cells is associated 
with increased apoptosis induced by 1a (see ESI).  
The observed preferential cytotoxicity of the 1a helicate 
against the p53-null cancer cell clones is highly significant as 
mutations in the p53 gene leading to loss of p53 tumour 
suppressor function are very common in cancers and are 
typically associated with poor clinical outcome.37-38 There is an 
urgent need for new chemotherapeutic agents that are effective 
against such cancers. The approach advocated here is to 
identify novel compounds that are active against cells that lack 
p53. Small molecule organometallic compounds including 
ruthenium (II) compounds have been shown to induce cell death 
via p53-dependent and independent mechanisms39 but typically, 
the clinically approved platinum based complexes are less active 
against p53-deficient cells than wild-type cells (Fig 5).40 The 
demonstration that the [Ru2(L
1)2]
4+ helicate is significantly more 
potent against p53 null HCT116 cells is therefore a significant 
finding in the context of finding drugs that target hard to treat 
p53-null tumours. In addition to selectivity towards HCT116 p53-
/- cells, 1a helicate is selectively toxic towards tumour cells 
compared to normal colon epithelia cells (Fig 5c). In contrast to 
the established platinates, selectivity for HCT116 cells as 
opposed to both normal colon epithelia CoN cells (Fig 5c) and 
non-cancer ARPE-19 cells (see ESI) was significantly higher. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Potency and selectivity towards p53 wild-type and p53 null HCT116 
colorectal carcinoma cells in vitro. a) The potency of IC50. b) Differential 
selectivity of compounds towards either the p53
+/+
 or the p53
-/-
 HCT116 cancer 
cells. c) Selectivity index for HCT116 p53
-/-
 and HCT116 p53
+/+ 
cells relative to 
normal colon epithelia CoN cells. The asterix indicates that for 1a helicate, true 
selectivity index values could not be determined as no IC50 could be obtained 
against CoN cells at the highest concentration (50 μM) tested. 
UV thermal melting profiles for ctDNA in the absence and 
presence of 1a are shown in Fig 7. These revealed a 
concentration dependent shift of the DNA melting temperature 
(Tm) indicating that ruthenium helicate 1a is able to stabilise 
genomic DNA. At ligand concentrations of 4 M and above, 
there was evidence of ligand redistribution and therefore the Tm 
analysis breaks down. At all ligand concentrations and the 
higher temperature region, the melting profile was 
disproportionately shifted to the right indicating a marked 
preference for stabilisation of GC- rather than AT-rich 
sequences (Fig 7). 
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Figure 6. Validation of the role of p53 in the response of cells to helicate 1a. a) 
represents the transfection of wild-type p53 or vector control into HCT116 p53
-
/-
 cancer cells (left hand side) and modulation of p53 protein expression levels 
in these cells is indicated by immunoblot analyses. Representative images of 
vector control cells and transfected cells treated with or without 1a is 
presented on the right-hand side. These results demonstrate that transfection 
of wild type p53 into p53 null cells significantly reduces the potency of 1a. b) 
the effect of p53 knockdown in HCT116 p53
+/+
 cells using siRNA on the 
potency of 1a. SiRNA knockdown partially reduced the expression of p53 as 
indicated in the immunoblot images and caused a small but statistically 
significant increase in the potency of 1a. Representative images of cells 
treated with 1a are presented on the right-hand side.  
 
 
 
 
 
 
 
 
Figure 7. The interaction of helicate 1a with DNA.  Normalised thermal melting 
profiles of calf thymus DNA (50 μM) in the absence and presence of 1a (from l 
to r, [1a] = 0, 0.5, 1, 2, 3, 4, 5 μM). All samples contained 0.25% DMSO. 
The parameter Tm
80/Tm
20
 provides a semi-quantitative 
indication of the excess of GC over AT stabilisation41 and whilst 
a Tm
80/Tm
20
  1 indicates no sequence preferential effect on 
the melting curve, 1a helicate generated a Tm
80/Tm
20 >>1 
indicates a marked preference for stabilising GC-rich sequences 
(see ESI). ICP-MS studies demonstrated that 1a helicate is 
taken up into the nucleus of cells (see ESI). The levels of 1a 
helicate in both HCT116 p53+/+ and HCT116 p53-/- cells are 
similar suggesting that differential drug uptake is unlikely to 
explain the increased sensitivity of HCT116 p53-/- cells to 1a 
helicate.  
 Helicate 1a was found to induce cell death by apoptosis in 
both HCT116 p53+/+ and p53-/- cancer cells. The proportion of 
cells in late stage apoptosis were higher in the p53-/- cancer cells 
than their p53+/+ isogenic clones (Fig 8) correlating with the 
preferential cytotoxicity in chemosensitivity assays of 1a towards 
p53-/- cells.    
 
 
 
 
 
 
Fig. 8. Summary of the percentage of early and late apoptotic cells (annexin 
V-positive) in response to treatment of HCT116 p53
+/+ 
and p53
-/-
 cells with 1a 
helicate or solvent control. 
In light of the observed binding of 1a to DNA and its nuclear 
localization, its ability to inhibit topoisomerases I and IIα was 
determined. 1a induced a dose dependent, partial inhibition of 
topoisomerase IIα (Fig. 9). The exact mechanism of inhibition is 
not known but is consistent with its ability to bind to DNA. In 
contrast, no inhibition of topoisomerase I was observed. Whilst 
p53 proficiency or deficiency does not affect cellular response to 
topoisomerase I inhibitors,42 p53 deficiency is known to sensitize 
cells to topoisomerase II inhibitors.43 It is possible therefore that 
the observed selectivity of 1a helicate for p53 null cells is 
mediated through inhibition of topoisomerase II.   
 
Fig. 9. Inhibition of purified human topoisomerase II α by helicate 1a. Lanes 1 
and 2 represent control reactions with (lane 2) and without (lane 1) 
topoisomerase present. Lane 3 represents a control reaction without 
topoisomerase enzymes present but with 1a at 10 μM. Lanes 4 to 8 represent 
reactions in the presence of 1a at 10μM (lane 4), 5μM (lane 5), 2.5 μM (lane 6), 
1.25 μM (lane 7) and 0.625 μM (lane 8). SC and OC denote the supercoiled 
and open circular forms of pBR322 DNA respectively.  
 This study gives valuable insight into the chemical 
composition and the shapes of the helicate system that are 
required to form species that are, a) selectively active against 
cancer cells as opposed to normal cells and, b) have preferential 
cytotoxicity towards cells either lacking or expressing the tumour 
suppressor p53. Compared with the mononuclear form, it is 
clear from the data presented that the dinuclear nature of the 
helicate is required to form a derivative that is preferentially 
selective towards cancer cells either with or without p53 
(comparison of [Ru(L1)2]
2+ vs [Ru2(L
1)2]
4+). The data also 
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suggests that the type of twist present within the system (e.g. 1a 
helicate vs 1b mesocate) can switch the direction of p53 
selectivity. However, subtle changes in the ligand strand can 
result in a significant reduction in the toxicity as very little activity 
was observed upon the introduction of a methyl unit (e.g. 2a 
helicate and 2b mesocate) or using a diphenyl spacer (e.g. 
helicate-[Ru2(L
4)2]
4+). These findings indicate that the helicate 
structure can be ‘fine-tuned’ with profound downstream effects 
both on toxicity and p53 selectivity. Given the frequent loss of 
p53 tumour suppressor function in cancers as well as p53 
mutations that can result in oncogenic gain of function, this study 
demonstrates that the helicate system is worthy of future 
investigation as an emerging potential source of new anti-cancer 
drugs.  
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